This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Leptin Levels in Papillary Thyroid Cancer (LL-PTC)

This study has been completed.
Information provided by (Responsible Party):
Whitney Goldner, MD, University of Nebraska Identifier:
First received: August 3, 2012
Last updated: May 9, 2017
Last verified: May 2017
The purpose of this study is to evaluate Leptin levels in females, in the setting of papillary thyroid cancer, benign thyroid nodules, and in normal females without thyroid disease.

Thyroid Cancer, Papillary Leptin Levels

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: Assessment of Serum Leptin Levels in Females With Papillary Thyroid Carcinoma, Benign Thyroid Nodules, and Normal Controls

Resource links provided by NLM:

Further study details as provided by Whitney Goldner, MD, University of Nebraska:

Primary Outcome Measures:
  • evaluating Leptin level Evaluating Serum Leptin Levels Between 3 Groups. One Group with Papillary Thyroid Carcinoma. One Group With Benign Nodules. One Group with Normal Thyroid. [ Time Frame: During Study ]
    Assessing serum leptin levels in females with treated papillary thyroid carcinoma and compared to females with proven benign thyroid nodules and females with normal thyroid glands. All groups were matched by gender, age, and BMI to limit confounders.

Enrollment: 18
Study Start Date: August 2012
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Detailed Description:
There will be three groups in this study, but 2 of the groups are part of another study so will only recruit normal controls.

Ages Eligible for Study:   19 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Females with no prior history of thyroid disease and not on thyroid medications.

Active recruitment will be for normal controls only. They will be age and weight/height matched to females with prior diagnosis of thyroid cancer or thyroid nodules who are already part of another study.


Inclusion Criteria:

  • Female
  • Age>/- 19
  • Not currently pregnant or lactating
  • Normal thyroid gland by history

Exclusion Criteria:

  • Male Gender
  • Pregnancy
  • Lactation
  • Age below 19
  • Abnormal thyroid gland by history
  • Abnormal thyroid gland by structure using ultrasound
  • Abnormal thyroid gland by function using TSH, Free T4
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01659385

United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Sponsors and Collaborators
University of Nebraska
Principal Investigator: Whitney Goldner, MD University of Nebraska
  More Information

Responsible Party: Whitney Goldner, MD, Principal Investigator, University of Nebraska Identifier: NCT01659385     History of Changes
Other Study ID Numbers: 276-12-EP
Study First Received: August 3, 2012
Last Updated: May 9, 2017

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type processed this record on July 19, 2017